Adrian Bebenek
@AdrianBebenek
Followers
408
Following
330
Media
5
Statuses
385
Fellow @Vida_Ventures || @Harvard Chem Bio PhD Candidate @SchreiberStuart @TheXavierLab Labs || @Yale B.S. @CraigMCrews Lab || šµš±
Joined April 2013
RT @CellChemBiol: Development of an FKBP12-recruiting chemical-induced proximity DNA-encoded library and its application to discover an autā¦.
0
9
0
RT @AppleHelix: I think this will become much more common going forward. Pharma in-licensing IND-enabled or Phase 1 assets. Frankly, thisā¦.
0
2
0
Generate videos in just a few seconds. Try Grok Imagine, free for a limited time.
575
2K
8K
RT @TheXavierLab: New work out now @CellChemBiol! We developed a non-degrader CIP-DEL platform for discovery of modulators of protein-proteā¦.
0
6
0
RT @TheXavierLab: (1/5) Excited to share this collab with the Cravatt lab at @scrippsresearch! A structurally diverse library of photoreactā¦.
0
5
0
RT @Vida_Ventures: #CandidTherapeutics, led by Ken Song, launched today with $370M in funding. Vida is proud to support Candid as it develoā¦.
businesswire.com
Candid Therapeutics, Inc. (āCandidā), a biotechnology company dedicated to developing potentially transformative drugs to address autoimmune diseases, announ...
0
1
0
RT @realJimWells: Big day for the lab as our MultiMap platform is now published on Science! Congratulations to Lindsey @Zhi_Lindsey_Lin andā¦.
science.org
Proximity labeling proteomics (PLP) strategies are powerful approaches to yield snapshots of protein neighborhoods. Here, we describe a multiscale PLP method with adjustable resolution that uses a...
0
14
0
RT @fperrywilson: Well we finally got an Ozempic vs. Mounjaro head-to-head (kind of). Brief thread to break down the weight-loss-drug shā¦.
0
122
0
RT @adamfeuerstein: $LLY buyinng $MORF $3.2B - oral integrin for inflammatory bowel disease. $57 per share. 78% premium. .
prnewswire.com
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Morphic Holding, Inc. (NASDAQ: MORF) today announced a definitive agreement for Lilly to acquire Morphic,...
0
17
0
RT @XWang829: Previous papers have shown that drug targets with supporting genetic evidence can have twice the success rate when reaching cā¦.
medrxiv.org
90% of therapeutic programs that enter clinical trials ultimately fail. Human genetic variation provides a set of ānatural experimentsā that can inform successful strategies for therapeutic discove...
0
26
0
RT @JorgeCondeBio: Recent draft guidance from @US_FDA on 'platform technology designation' would enable companies to reuse prior data for fā¦.
0
40
0
RT @Pharmdca: $VKTX . Infact $AMGN discontinuing Oral drug either due to low efficacy or Safety issues is big positive for $VKTX . $AMGN Reā¦.
0
8
0
RT @ptimshel: Does single-cell data increase probability of success in drug discovery and clinical success? š§.Drug targets backed by singleā¦.
0
20
0
RT @RapeLab: Congratulations to #MolecularTherapeutics faculty @bignerdzzy and @kevansf on their wonderful paper on targeting the G12D variā¦.
nature.com
Nature Chemical Biology - Development of a malolactone electrophile that contains sufficient ring strain to counteract the weak nucleophilicity of aspartate enables covalent targeting of...
0
17
0
RT @PharmDabbler: $VKTX obesity market has all the momentum. Likely suitors: .- $PFE - just pulled their Ph3 trial from Danuglipron twiceā¦.
0
8
0
RT @bloodgenes: Wonderful to have our paper, "Inherited blood cancer predisposition through altered transcription elongation", published (oā¦.
0
72
0
Congratulations @SchreiberStuart! I am very excited to see all that comes out of @arenabioworks ā a new model for drug discovery is desperately needed! .
nytimes.com
Arena BioWorks is promising big paydays to nearly 100 researchers from Harvard, M.I.T. and other prestigious institutions.
0
1
6
RT @DanNomura: Congrats to our chem bio grad student Margot Meyers @MeyersM037 on her ACS Chem Bio paper on the discovery of a covalent DDā¦.
pubs.acs.org
Targeted protein degradation has arisen as a powerful therapeutic modality for eliminating proteins. Thus far, most heterobifunctional proteolysis targeting chimeras (PROTACs) have utilized recruit...
0
11
0
Congrats to @_chrisgparker_ and team on the dev of a covalent (PPI) inhibitor of SLC15A4 ā highlighting the power of chemoproteomics for IDing modulators of difficult membrane targets. Love all the attn to I&I this last year
nature.com
Nature Chemical Biology - Integrated chemoproteomic development of selective small-molecule SLC15A4 inhibitors and their functional characterization establish SLC15A4 as a druggable target for...
1
1
23
RT @doctorveera: GWAS and ExWAS of human hypothalamus volumes identify a strong association with ADAMTS8 (encodes an angiogenesis-inhibitinā¦.
0
10
0
RT @pottslab: CAND1 is a conditional inhibitor for CRL2 E3s dependent on CRL2 substrate Kd. Unlike CRL1 E3s that have fast on rates, CRL2 Eā¦.
nature.com
Nature Structural & Molecular Biology - Here, the authors demonstrate that CAND1 increases the dissociation rate of CRL2s, thus exerting an inhibitory effect, which in turn endows CRL2s with a...
0
5
0